HomeCompareCUTR vs ABBV

CUTR vs ABBV: Dividend Comparison 2026

CUTR yields 2063.98% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CUTR wins by $13331039307.11M in total portfolio value
10 years
CUTR
CUTR
● Live price
2063.98%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13331039307.22M
Annual income
$12,171,036,297,947,368.00
Full CUTR calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CUTR vs ABBV

📍 CUTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCUTRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CUTR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CUTR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CUTR
Annual income on $10K today (after 15% tax)
$175,438.60/yr
After 10yr DRIP, annual income (after tax)
$10,345,380,853,255,262.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CUTR beats the other by $10,345,380,853,234,206.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CUTR + ABBV for your $10,000?

CUTR: 50%ABBV: 50%
100% ABBV50/50100% CUTR
Portfolio after 10yr
$6665519653.66M
Annual income
$6,085,518,148,986,070.00/yr
Blended yield
91.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CUTR
Analyst Ratings
4
Buy
5
Hold
Consensus: Hold
Price Target
$39.25
+40405.7% upside vs current
Range: $1.00 — $68.00
Altman Z
-2.8
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CUTR buys
0
ABBV buys
0
PoliticianChamberTickerTypeAmountDate
Tina Smith🏛 Senate$CUTR▼ Sell$100,001 - $250,0002018-08-30
Tina Smith🏛 Senate$CUTR▼ Sell$1,001 - $15,0002018-08-30
Tina Smith🏛 Senate$CUTR▼ Sell$1,001 - $15,0002018-08-30
Tina Smith🏛 Senate$CUTR▼ Sell$250,001 - $500,0002018-01-16
Tina Smith🏛 Senate$CUTR▼ Sell$250,001 - $500,0002018-01-16
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCUTRABBV
Forward yield2063.98%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$13331039307.22M$102.3K
Annual income after 10y$12,171,036,297,947,368.00$24,771.77
Total dividends collected$13248903950.40M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$39.25$256.15

Year-by-year: CUTR vs ABBV ($10,000, DRIP)

YearCUTR PortfolioCUTR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$217,098$206,398.35$11,550$430.00+$205.5KCUTR
2$4,420,028$4,187,732.78$13,472$627.96+$4.41MCUTR
3$84,412,065$79,682,634.57$15,906$926.08+$84.40MCUTR
4$1,512,516,762$1,422,195,852.90$19,071$1,382.55+$1512.50MCUTR
5$25,434,529,072$23,816,136,137.07$23,302$2,095.81+$25434.51MCUTR
6$401,507,365,308$374,292,419,200.69$29,150$3,237.93+$401507.34MCUTR
7$5,951,621,357,208$5,522,008,476,328.59$37,536$5,121.41+$5951621.32MCUTR
8$82,867,113,366,068$76,498,878,513,854.90$50,079$8,338.38+$82867113.32MCUTR
9$1,084,114,961,932,747$995,447,150,631,054.80$69,753$14,065.80+$1084114961.86MCUTR
10$13,331,039,307,215,410$12,171,036,297,947,368.00$102,337$24,771.77+$13331039307.11MCUTR

CUTR vs ABBV: Complete Analysis 2026

CUTRStock

Cutera, Inc., a medical device company, researches, develops, manufactures, markets, and services laser and energy-based aesthetics systems for practitioners worldwide. The company offers Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truSculpt flex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; excel V+, a vascular and benign pigmented lesion treatment platform; truSculpt iD, for the non-surgical body sculpting market; and Secret RF, a fractional RF microneedling system for tissue coagulation and hemostasis. It also provides enlighten platform, a laser system that is used for tattoo removal, as well as to treat benign pigmented lesions and acne scars; excel HR platform, a hair removal solution for various skin types; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity. In addition, the company distributes skincare products; and offers post-warranty services through extended service contracts or direct billing. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; and Pearl and Pearl Fractional hand pieces, as well as sells hand piece refills, cycle refills, consumable tips, and marketing brochures through the company's website. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, and other qualified practitioners, as well as for physicians performing aesthetic treatments in non-medical offices. Cutera, Inc. was incorporated in 1988 and is headquartered in Brisbane, California.

Full CUTR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CUTR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CUTR vs SCHDCUTR vs JEPICUTR vs OCUTR vs KOCUTR vs MAINCUTR vs JNJCUTR vs MRKCUTR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.